Forum Co-Chairs
Co-Founder, Penn
Amyloidosis Center
Professor of Neurology
University of Pennsylvania
School of Medicine
Philadelphia, PA
Indiana University Amyloidosis
Research Group
Associate Professor of
Clinical Medicine
Indiana University School of Medicine
Indianapolis, IN
Director, Cardiac
Amyloidosis Program
Assistant Professor of Medicine
Oregon Health & Science University
Portland, OR
Roland Seidler, Jr. Professor of Medicine
Chair, Internal Medicine
Hem/Onc/Internist
Mayo Clinic
Rochester, MN
Wiesman Award Winners
Senthil Selvaraj, MD, MS, MA (2024)
Dr. Selvaraj is an Assistant Professor of Medicine, Advanced Heart Failure and Transplant Cardiologist, Faculty Member of the Duke Molecular Physiology Institute, Executive Faculty in the Center for Precision Health, and Faculty Lead of Heart Failure Research at Duke University. A fundamental goal of his research includes advanced imaging and epidemiological characterization of infiltrative cardiomyopathies including ATTR-CA. This line of inquiry has investigated the impact of the amyloidogenic V142I transthyretin variant on individual and population levels (including Selvaraj et al., Circ Heart Fail, 2025; Selvaraj et al., JAMA, 2024; Selvaraj et al., JAMA Cardiology, 2023, Selvaraj et al., JACC, 2021). His work is currently, or has recently, been supported by an NHLBI K23 and R03, AHA career development award, Doris Duke Physician Scientist Fellowship Award, American Society for Nuclear Cardiology award, Measey Foundation Award, Mandel Foundation grant, Duke Heart Center Leadership Council award, Institute for Translational Medicine and Therapeutics grant, Foundation for Sarcoidosis Research, and Winn Foundation. Future work aims to characterize the age-dependent penetrance of the V142I variant leveraging deep phenotyping alongside investigating modifiers of risk.
Ani Nalbandian, MD, MPH (2024)
Dr. Ani Nalbandian completed medical school at Columbia University Vagelos College of Physicians & Surgeons, followed by Internal Medicine Residency and General Cardiology Fellowship at Columbia University Irving Medical Center-New York Presbyterian Hospital. During cardiology fellowship, she completed a Master’s in Patient Oriented Research at the Mailman School of Public Health, and conducted a pilot clinical trial investigating body composition analysis and sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy which was supported by a T32 NIH-funded Training Grant and the Glorney-Raisbeck Fellowship Award in Cardiovascular Diseases granted by the New York Academy of Medicine. Following cardiology fellowship, Dr. Nalbandian completed an additional 1-year ACGME-accredited fellowship in Critical Care Medicine at Columbia University Irving Medical Center-New York Presbyterian Hospital, becoming the inaugural dual-boarded critical care cardiologist trained at the institution.
Dr. Nalbandian joined as faculty in the Division of Cardiology in August 2024, where she attends primarily as a cardiac intensivist, and also has a general outpatient clinical practice. She was recently awarded the 1st Annual Wiesman Award for Excellence in Early-Career ATTR Research by Cornerstone Medical Education (with independent support from AstraZeneca and Ionis Pharmaceuticals), granting her the ability to continue her clinical research within this field of interest. In addition, Dr. Nalbandian aspires to help develop a longitudinal multi-disciplinary care clinic for patients post critical illness, serving both clinical and research needs of this growing patient population.
Evangelos Oikonomou, MD, DPhil (2025)
Evangelos (Evan) K. Oikonomou, MD, DPhil, is a cardiologist-data scientist, and an Assistant Professor at the Yale School of Medicine. His research focuses on developing multimodal artificial intelligence (AI) tools that combine common cardiac diagnostics and electronic health record data to enable targeted digital screening for transthyretin amyloid cardiomyopathy (ATTR-CM). His recent work includes a multicenter study on the AI-guided detection of ATTR-CM using point-of-care ultrasonography (Lancet Digital Health 2025, PMID: 39890242), a multimodal ECG-echo biomarker that tracks the preclinical progression of ATTR-CM (Eur Heart J 2025, PMID: 40679604), and a foundation-model framework for precision deployment of AI-ECG screening (TARGET-AI). His future work aims to translate these AI-based biomarkers into pragmatic clinical workflows to enable the timely diagnosis of ATTR-CM.
Michael Chetrit, MD, FACC (2025)
Michael Chetrit received his medical doctorate from the University of Montreal in Montreal, Canada. He completed his training as an internist and cardiologist at the McGill University Health Centre, McGill University in Montreal as well. He completed additional training at the Cleveland Clinic, in Cleveland Ohio where he gained expertise in advanced cardiac imaging including cardiac MRI. He also trained in cardiac amyloidosis and pericardial diseases. He is currently assistant professor with the department of Medicine at McGill University and a staff cardiologist at the McGill University Health Center. In addition to directing the McGill Amyloidosis Project and the MUHC Pericardial diseases clinic, he remains an active researcher with interest in CMR and cardiac amyloidosis as well as multiparametric and artificial intelligence applications in CMR.
© All Rights Reserved.